The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of AbbVie's upadacitinib (Rinvoq) to treat adults ... to receive a 7.5 mg or 15 mg ...

It seems the EU regulator is not so concerned about the safety signal, clearing both 15mg and 30mg daily doses of Rinvoq for adults with atopic dermatitis, and a 15mg dose for adolescents and the ...

less effective dose, as well as warnings for serious infections, cancer and blood clots on its label. Rinvoq hasn’t sidestepped those concerns, and its label also warns of the blood clot risks.